Recently, more and more studies have shown that the biomarker candidate proteins in the annexins family are potentially instrumental in the progression of various cancers; e.g., ANXA1 for clear cell renal cancer, ANXA2 for gastric cancer and colorectal cancer, ANXA4 for colorectal cancer, ANXA8 for breast cancer, ANXA10 for hepatocellular cancer, ANXA11 for ovarian cancer and colorectal cancer [35]. This evidence concerns the gene ANXA2 and clear cell renal carcinoma.